ARCHIVES

No Difference in Toxicity Between IMRT and PRT In Medicare Patients

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

CMS Launches National Coverage Analysis, Citing FDA’s Black Box Warning on ESAs.

March 16, 2007

ODAC Recommends Femara Campath For FDA Approval.

January 5, 2001

In Brief: General Motors Cancer Research Foundation Prizewinners: Brock, Li, Fraumeni, Harlow

June 16, 1995

Hydridoma Cell Lines Available

March 5, 1982

NIH Cool On OIG, But the Awardees Love it, DeVita Says

October 17, 1986

Arthur Upton New Name In Director Race; Califano Meets With Prospects

May 6, 1977